First Trust Advisors LP lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 381,706 shares of the company’s stock after selling 15,024 shares during the period. First Trust Advisors LP’s holdings in Eli Lilly and were worth $32,651,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of LLY. Acrospire Investment Management LLC increased its holdings in shares of Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC bought a new stake in shares of Eli Lilly and in the 2nd quarter worth $128,000. San Francisco Sentry Investment Group CA bought a new stake in shares of Eli Lilly and in the 2nd quarter worth $129,000. Point72 Asia Hong Kong Ltd increased its holdings in shares of Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares in the last quarter. Finally, Shine Investment Advisory Services Inc. bought a new stake in shares of Eli Lilly and in the 2nd quarter worth $148,000. 76.43% of the stock is owned by institutional investors.

LLY has been the subject of a number of research analyst reports. Jefferies Group reissued a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a report on Monday, September 11th. BMO Capital Markets reissued an “underperform” rating and issued a $71.00 target price (down previously from $73.00) on shares of Eli Lilly and in a report on Wednesday, September 6th. Credit Suisse Group lowered Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $84.23 to $88.00 in a report on Tuesday, October 10th. Piper Jaffray Companies reissued an “overweight” rating and issued a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a report on Friday, September 8th. Finally, Berenberg Bank reissued a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $90.25.

Eli Lilly and Company (NYSE LLY) traded up $0.26 during midday trading on Tuesday, reaching $85.58. The company had a trading volume of 4,228,200 shares, compared to its average volume of 3,671,792. The stock has a market capitalization of $93,945.43, a P/E ratio of 20.86, a PEG ratio of 1.87 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 12 month low of $66.39 and a 12 month high of $89.09.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.88 earnings per share. sell-side analysts anticipate that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.43%. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold 592,003 shares of company stock worth $50,246,641 over the last quarter. 0.20% of the stock is owned by company insiders.

WARNING: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/first-trust-advisors-lp-has-32-65-million-position-in-eli-lilly-and-company-lly/1745358.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.